 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory...

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure N.V. ( NASDAQ:QURE ) shares have had a horrible month, losing 29% after a relatively good period beforehand...

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Volume (M)	432,949.00
52-Wk High	$22.48
52-Wk Low	$4.62

QURE uniQure N.V.

About

Feed

News

Sentiment

Earnings

Fundamentals